Kei Suzuki

Research Fellow (2013 - 2014)
Office Phone:
212-639-8158

Awards and Scholarships

  • New York State Empire Clinical Research Investigator Program (ECRIP) 
  • Commission on Cancer Research Award, 2011 Society of Thoracic Surgeons’ “Look to the Future” Scholarship

Current Employment

  • Thoracic Surgery Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY
Publications by Kei Suzuki

Manuscripts

- Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014 Feb 15;20(4):1020-8. PMID: 24334761; PMCID: PMC3944669.

Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011 May;6(5):896-904. PMID 21358344

Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, Kachala SS, Zlobinsky M, Rusch VW, Adusumilli PS*. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol. 2011 Apr;6(4):762-7. PMID 21325982

Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS*. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011 Aug 15;17(16):5247-56. PMID 21659461

Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS*. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epitheliod malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011 Dec;60(12):1721-8. PMID 21769693

Kadota K, Suzuki K , Vertes E, Colovos C, Morales E, Sadelain M, Adusumilli PS*. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011 Nov;60(11):1509-27. PMID 21913025

Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleischer M, Rusch VW, Sadelain M, Adusumilli PS*. An in vivo platform for tumor biomarker assessment. PLoS One 2011;6(10):e26722. PMID 22046338

Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MPS, Sima CS, Travis WD, Rusch VW, Adusumilli PS*. High-SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as non-epithelioid histology. J Thorac Oncol 2012;7(7):1192-7. PMID 22617244.

Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, Zabor EC, Sima CS, Yoshizawa A, Travis WD, Rusch VW, Adusumilli PS*. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 2012; 19(11):3598-605. PMID 22644511

Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis W, Sadelain M, Adusumilli PS*. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor IL-12R & IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013;31(4):490-498. PMID 23269987

Abstracts/Presentations

Servais EL, Nitadori J, Morales EA, Suzuki K, Bograd AJ, Rizk NP, Downey RJ, Rusch VW, Adusumilli PS. Pre-operative consolidation to tumor ratio on computed tomography and FDG-PET SUVmax predict recurrence after limited resection of early lung adenocarcinoma. American Association for Thoracic Surgery 2012, May 2012, San Francisco, CA.

Kadota K, Yeh YC, Suzuki K, Sima CS, Rusch VW, Moreira AL, Adusumilli PS, Travis WD. Cribriform pattern identifies a poor prognostic subset of acinar predominant tumors in stage I lung adenocarcinoma patients. United States and Canadian Academy of Pathology, March 17-23, 2012, Vancouver, Canada. Laboratory Investigation Feb2012;92(1):479A; Mod Pathol;25(2):479A

Kadota K, Nitadori J, Suzuki K, Sima CS, Yoshizawa A, Rusch VW, Travis WD, Adusumilli PS. Thyroid transcription factor-1 expression correlates with predominant histologic subtypes and recurrence in stage I lung adenocarcinoma patients. United States and Canadian Academy of Pathology, March 17-23, 2012, Vancouver, Canada. Laboratory Investigation Feb2012;92(1):479A; Mod Pathol;25(2):479A

Kachala SS, Suzuki K, Vertes E, Rodriguez L, Kadota K, Sima CS, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin is a commonly expressed tumor marker in lung adenocarcinoma (LAC) that imparts an aggressive phenotype—a candidate molecular target. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.

Kadota K, Suzuki K, Yoshizawa A, Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS, Travis WD. Clinicopathologic characteristics of adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and lepidic predominant (LPD) adenocarcinoma of the lung (LAC): Memorial Sloan-Kettering Cancer Center experience. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.

Kadota K, Suzuki K, D’Angelo, SP, Rekhtman N, Moreira AL, Sima CS, Riely GJ, Kris MG, Rusch VW, Adusumilli PS, Travis WD. Molecular correlation with histologic patterns of mucin in lung adenocarcinoma (ADC). International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.

Kadota K, Suzuki K, Zabor EC, Sima CS, Rizk NP, Rusch VW, Travis WD, Adusumilli PS. PET SUVmax in stage I lung adenocarcinoma (LAC) is a predictor of recurrence, correlates with the new IASLC/ATS/ERS histological classification, and further stratifies prognosis in intermediate-grade acinar / papillary subtype. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.

Kadota K, Suzuki K, D’Angelo SP, Rekhtman N, Moreira AL, Sima CS, Riely GJ, Azzoli CG, Kris MG, Rusch VW, Adusumilli PS, Travis WD. Validation of the proposed IASLC/American Thoracic Society (ATS)/European Respiratory Society (ERS) international multidisciplinary classification of lung adenocarcinoma (ADC). International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.

Nitadori J, Bograd AJ, Kadota K, Sima CS, Morales E, Suzuki K, Rizk NP, Rusch VW, Travis WD, Adusumilli PS. Micropapillary morphology is an independent predictor of recurrence in patients undergoing limited resection for lung adenocarcinoma (LAC) ≤2cm. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.

Suzuki K, Kadota K, Sima CS, Rusch VW, Sadelain M, Travis WD, Adusumilli PS. Tumor immune microenvironment in stage I lung adenocarcinoma (LAC): stromal FoxP3/CD3 ratio, tumor IL7R, and IL12Rβ2 are independent predictors of recurrence. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands

Kadota K, Suzuki K, Rusch VW, Moreira AL, Adusumilli PS, Travis WD. Nuclear grading system predicts recurrence in stage I lung adenocarcinoma patients. United States and Canadian Academy of Pathology, February 26-March 4, 2011, San Antonio, TX. Laboratory Investigation Feb 2011;91(1):413A-414A; Mod Pathol;24(1):413A-414A

Kadota K, Suzuki K, Sima C, Rusch VW, Adusumilli PS, Travis WD. Cytologic grading is an independent prognostic factor in epithelioid diffuse malignant pleural mesothelioma. United States and Canadian Academy of Pathology, February 26-March 4, 2011, San Antonio, TX. Mod Pathol Feb 2011; 24(1):414A; Laboratory Investigation Feb 2011;91(1):414A.

Servais EL, Suzuki K, Fleisher M, Sima C, Colovos C, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. An in vivo platform for biomarker validation in malignant pleural mesothelioma. 10th International Conference of the International Mesothelioma Interest Group (IMIG), August 31-September 3, 2010, Kyoto, Japan.

Suzuki K, Kadota K, Sima C, Zakowski MF, Rusch VW, Travis WD, Adusumilli PS. Stromal chronic inflammatory response is a significant predictor of survival in epithelioid diffuse malignant pleural mesothelioma (DMPM). 10th International Conference of the International Mesothelioma Interest Group (IMIG), August 31-September 3, 2010, Kyoto, Japan.

Kadota K, Suzuki K, Sima C, Zakowski MF, Rusch VW, Adusumilli PS, Travis WD. Significance of pleomorphic, solid, and micropapillary subtypes in epithelioid diffuse malignant pleural mesothelioma (DMPM). 10th International Conference of the International Mesothelioma Interest Group (IMIG), August 31-September 3, 2010, Kyoto, Japan.

Suzuki K, Servais EL, Sima C, Kachala SS, Rizk NP, Park B, Rusch VW, Adusumilli PS. Outcomes of indwelling tunneled pleural catheters for malignant pleural effusion: the role for surgical evaluation. Oral presentation in surgical forum: American College of Surgeons 96th Annual Clinical Congress, October 3-7, 2010, Washington, DC.

Servais EL, Colovos C, Suzuki K, Velez M, Rodriguez L, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM). Oral presentation in surgical forum: American College of Surgeons 96th Annual Clinical Congress, October 3-7, 2010, Washington, DC.

Servais EL, Colovos C, Suzuki K, Rodriguez L, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Biomarker validation for a rare malignancy in a mouse model. AACR 100th Annual Meeting, April 17-20, 2010, Washington, DC.